Related Experiment Video
Updated: Jul 20, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management
Miguel A Gonzalez-Gay1, Carlos Garcia-Porrua, Jose A Miranda-Filloy
1Division of Rheumatology, Hospital Xeral-Calde, Lugo, Spain. miguelaggay@hotmail.com
Drugs & Aging
|September 13, 2006
Summary
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are common inflammatory conditions in older adults. Corticosteroids are the primary treatment, but long-term use and complications like visual loss require careful management and alternative therapies.
Area of Science:
- Rheumatology
- Internal Medicine
- Vasculitis
Background:
- Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are prevalent inflammatory conditions affecting individuals over 50.
- GCA primarily impacts cranial arteries, while PMR causes pain and stiffness in the neck, shoulders, and hips.
- Both diseases typically present with elevated inflammatory markers like ESR and CRP.
Purpose of the Study:
- To review the clinical features, diagnosis, and management of GCA and PMR.
- To highlight the role of corticosteroids and discuss potential complications and alternative treatments.
Main Methods:
- Literature review of GCA and PMR focusing on clinical presentation, diagnostic standards, and therapeutic approaches.
- Analysis of corticosteroid efficacy and side effects, including visual loss in GCA.
- Exploration of emerging therapies and management strategies.
Main Results:
- Temporal artery biopsy is the gold standard for GCA diagnosis.
- Corticosteroids are effective for both conditions, with differing initial dosages for GCA (40-60 mg/day) and PMR (10-20 mg/day).
- Visual loss in GCA is often irreversible, and some patients require long-term corticosteroid treatment.
Conclusions:
- Effective management of GCA and PMR relies on appropriate corticosteroid use and monitoring for complications.
- Corticosteroid-sparing agents and therapies targeting bone metabolism may offer benefits for long-term patient care.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...